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SUPPLEMENTARY RESULTS 
SUPPLEMENTARY TABLES 
 
Supplementary Table 1 | List of utilized cDNA constructs. 
 
Name Characterization 
R-GECO
24
 Red intensiometric Ca
2+
 sensor 
C1-GFP
21
 Green DAG-sensing translocation probe 
PKC-RFP* Protein kinase C  reporter 
PKC-GFP
30
  Protein kinase C  reporter 
CKAR
32
 Cytosolic C kinase activity reporter 
Munc13-1-GFP
10
 Munc13-1 translocation reporter 
Munc13-1
H567K
-GFP
10
 Munc13-1
H567K
 mutant translocation reporter 
 
*The PKC-RFP construct was prepared by exchanging the eGFP from the original construct
62
 with 
mRFP via the EcoRI and EcoRV sites in the MCS of pcDNA3 backbone. 
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SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure 1 | Optical control of C1-GFP translocation. In HeLa cells expressing C1-GFP, 
PhoDAG-1 (150 M) triggered the translocation of C1-GFP towards the plasma membrane on irradiation 
with  = 375 nm laser light. Scale bar = 20 M. 
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Supplementary Figure 2 | Quantification of C1-GFP translocation. (a) A representative fluorescence 
image detailing the cytoplasmic (CP) and plasma membrane (PM) sample regions used for translocation 
quantification. Displayed here is C1-GFP fluorescence after the application of PhoDAG-1 (400 M) and 
 = 375 nm irradiation. Scale bar = 20 M. (b) The GFP fluorescence intensities at the plasma membrane 
and cytoplasm of a representative cell after the application of PhoDAG-1 (200 M).  
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Supplementary Figure 3 | PhoDAG-1 enables spatial control of DAG signaling. In HeLa cells 
expressing C1-GFP and R-GECO, PhoDAG-1 (150 M) activation could be targeted to specific cells. In 
this case, only the left half of the field of view (gray bar) was photoactivated with  = 375 nm irradiation. In 
these cells, C1-GFP translocated towards the plasma membrane, alongside an increase in intracellular 
Ca
2+
 levels. The right half of the frame remained largely unaffected (white bar). Scale bar = 20 M. 
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Supplementary Figure 4 | Optical control of C1-GFP translocation in HeLa cells. (a) HeLa cells 
expressing C1-GFP and R-GECO were incubated PhoDAG-1 (150 M) followed by washing with buffer 
to remove extracellular compound. Translocation of C1-GFP towards the plasma membrane was 
observed on irradiation with  = 375 nm light. An increase in intracellular Ca
2+
 was also observed in the 
same cells (n = 12). (b) The chemical structure of 1,2-O-dioctanoyl-sn-glycerol (1,2-DOG) being liberated 
from caged 1,2-DOG (cg-1,2-DOG) on irradiation with  = 375 nm laser light. (c,d) The uncaging of cg-
1,2-DOG (100 M) led to C1-GFP translocation towards the plasma membrane in HeLa cells. After 
uncaging, the recovery was relatively slow. Shown are (c) fluorescence images of two representative 
cells, and (d) data averaged from multiple cells (n = 25), displayed as the plasma membrane to cytoplasm 
(PM/CP) fluorescence ratio. Error bars were calculated as s.e.m. Scale bar = 20 M. 
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Supplementary Figure 5 | Lipid chain length determines the localization and activity of the 
PhoDAGs. (a) In HeLa cells, trans-PhoDAG-3 (150 M) caused translocation of C1-GFP towards internal 
membranes on application. (b) The chemical structure of coumarin-labeled arachidonic acid (cg-AA), 
which localizes in internal membranes. (c,d) Representative fluorescence images showing the 
localization of cg-AA (100 M, fire) before (left) and after (right) the addition of (c) PhoDAG-1 (150 M) or 
(d) PhoDAG-3 (150 M). PhoDAG-3 quenched the coumarin fluorescence significantly more quickly than 
PhoDAG-1. Cell nuclei were stained with DRAQ-5 (green) as a reference. Scale bar = 20 M. 
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Supplementary Figure 6 | PhoDAG-1 induces an increase in intracellular Ca
2+
 in HeLa cells. HeLa 
cells were transfected with C1-GFP and R-GECO. (a) Before the application of PhoDAG-1, UV-A 
irradiation alone did not catalyze C1-GFP translocation. Application of trans-PhoDAG-1 (300 M) caused 
an increase in intracellular Ca
2+
 ([Ca
2+
]i) levels, however no translocation was observed until triggered by 
 = 375 nm irradiation (n = 6). (b) On photoactivation, a small increase in [Ca
2+
]i was observed, followed 
by a delayed, larger Ca
2+
 increase, displayed as representative traces from individual cells. (c) The TRPC 
channel inhibitor SKF-96365 (50 M) slightly decreased the Ca
2+
 influx after application of PhoDAG-3 
(150 M), but not on photoactivation (n = 54, gray), when compared to PhoDAG-3 alone (n = 16, black). 
Translocation is represented as the plasma membrane to cytoplasm (PM/CP) C1-GFP fluorescence ratio, 
while Ca
2+
 levels were plotted as the R-GECO fluorescence intensity normalized to the baseline 
fluorescence (F/Fmin). Error bars were calculated as s.e.m. 
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Supplementary Figure 7 | Optical control of protein kinase C. (a) In HeLa cells expressing 
PKC-RFP, translocation efficiency induced by PhoDAG-1 (100 M) decayed over multiple cycles of 
irradiation of the same length (28 s pulses at = 375 nm, n = 11). (b) Changing the time between UV-A 
pulses did not affect the magnitude of the translocation. Both the 60 s (n = 13) and 240 s (n = 15) 
intervals showed similar efficiencies. (c) PKC-GFP translocated towards the plasma membrane on 
isomerization to cis-PhoDAG-1 (150 M) (n = 3). Sequential photostimulations led to diminished 
efficiency, corresponding to a reduced Ca
2+
 response. [Ca
2+
]i levels (R-GECO) were displayed as the 
RFP fluorescence intensity and normalized to the baseline fluorescence (F/Fmin). (d,e) As shown by the 
cytosolic C Kinase Activity Reporter (CKAR), the application of (d) 1,2-DOG (300 M, n = 32) and (e) 
phorbol 12-myristate 13-acetate (PMA, 5 M, n = 31) produced an increase in the CFP/YFP emission 
ratio, indicating kinase activation. In both cases, the FRET change was immediately reversed on addition 
of the broadband PKC inhibitor Gö-6983 (10 M). (f,g) PhoDAG-3 (15 M) caused an increase in the 
CFP/YFP emission ratio on application, and a further increase on photoactivation. This effect was 
reversed by the application of chelerythrine chloride (C-Cl, 100 M) (n = 14). (h) The CKAR response in 
HeLa cells was compared between cells with (n = 37 orange) and without (n = 20, teal) the expression of 
exogenous PKC-RFP. Overexpression of PKC-RFP increased the CKAR response by 1.2 fold when 
compared to endogenous PKC expression only. Error bars were calculated as s.e.m. 
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Supplementary Figure 8 | Diacylglycerol generation decreases Ca
2+
 oscillations in MIN6 cells. Ca
2+
 
oscillations in glucose stimulated (20 mM) MIN6 cells were monitored using R-GECO (a) PhoDAG-1 (300 
M) caused a decrease in the overall [Ca
2+
]i level on photoactivation. Data was averaged over multiple 
cells (n = 23). (b) PhoDAG-3 (35 M) triggered a decrease in the whole-cell voltage activated L-type Ca
2+
 
channel (Cav) current, as shown by voltage ramps (70 to +50 mV over 5 s) from a representative cell. (c) 
UV-A or blue irradiation alone did not affect the Cav current (n = 8), while the application of 1,2-DOG (100 
M, n = 3) and the L-type Ca
2+
 channel blocker diltiazem (500 M, n = 3) decreased the magnitude of the 
whole-cell Cav current. (d) The application of 1,2-O-dioctanoyl-sn-glycerol (1,2-DOG, 100 M) led to a 
slow and permanent decrease in the frequency and intensity of Ca
2+
 oscillations (n = 25). (e) After the 
uncaging of caged 1,2-DOG (cg-1,2-DOG, 100 M), the frequency and intensity of the Ca
2+
 oscillations 
was immediately reduced, but recovered gradually over 20-30 min (n = 47). Bar graphs represent the 
number of detected high intensity Ca
2+
 oscillations (>50% of highest transient in each trace) within every 
60 s interval. Error bars were calculated as s.e.m.  
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Supplementary Figure 9 | UV-A illumination of MIN6 cells alone has no significant effect on Ca
2+
 
oscillations. Ca
2+
 oscillations in glucose-stimulated (20 mM) MIN6 cells were monitored using R-GECO. 
Shown are individual Ca
2+
 traces from representative cells (left), and a statistical analysis of the oscillation 
frequency averaged over multiple cells (right). Bar graphs represent the number of detected high intensity 
Ca
2+
 oscillations (>50% of highest transient in each trace) within every 60 s interval. 
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Supplementary Figure 10 |   Control experiments for electrophysiological studies in dissociated 
-cells. In primary mouse -cells: (a) PhoDAG-1 (200 M) had no effect on the Cav current (n = 5). (b) 
UV-A or blue-irradiation did not affect the Cav current (n = 8), while the application of 1,2-DOG (15 M) 
decreased the magnitude of the Cav current (n = 3). (c) UV-A or blue-irradiation also did not affect the 
delayed rectifier voltage-gated K
+
 channel (Kv) current (n = 4). Arachidonic acid (AA, 10 M) decreased 
the magnitude of the Kv current (n = 4). Error bars were calculated as s.e.m. 
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Supplementary Figure 11 | UV-A irradiation alone does not alter glucose-stimulated pancreatic 
islet activity. Ca
2+
 oscillations in intact mouse pancreatic islets were monitored by Fluo-2. (a,b) 
Photoactivation of PhoDAG-3 (100 M) triggered an increase in the oscillation frequency, displayed as 
(a) a representative trace from a single islet and (b) the average oscillation frequencies for several islets 
before and after  = 350 nm irradiation (n = 8). (c,d) UV-A irradiation ( = 350 nm) alone did not affect (c) 
the speed of the Ca
2+
 oscillations in islets stimulated by 11 mM glucose or (d) the insulin secretion 
stimulated by 16.7 mM glucose (G16.7) (n = 3 experiments from 3 animals). ns = not significant P>0.05, 
P>0.05. Error bars were calculated as s.e.m.  
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Supplementary Figure 12 | A C1 domain point mutant abolishes the sensitivity of Munc13-1 to 
PhoDAG-1. In HeLa cells, The DAG-insensitive Munc13-1
H567K
-GFP mutant translocation reporter did not 
translocate on the application of PhoDAG-1 (150 M) or after photoactivation with  = 375 nm light, even 
though an increase in [Ca
2+
]i levels was observed (n = 13). 
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Supplementary Figure 13 | PhoDAG-2 application does not affect the pipette series resistance in 
patch-clamp experiments. PhoDAG-2 and PhoDAG-3 are lipid compounds, and therefore might affect 
the series resistance of the patch pipette, which could lead to artifacts in the EPSC amplitude. Moreover, 
the compound integrates in the cell membrane where it might lead to changes in the cell size or 
membrane conductance. To exclude these effects, we performed a control experiment with PhoDAG-2 
and monitored series resistance and membrane capacitance, before and after illumination (n represents 
the number of illumination cycles; DMSO, black, for activation n = 9, for inactivation n = 8; PhoDAG-2, 
red, for activation n = 22, for inactivation n = 21). (a) The ratio of the change in the EPSC amplitude was 
calculated by dividing the average amplitude after photoactivation, by that before photoactivation. (b) The 
ratio of the change in EPSC charge was calculated by dividing the average charge after activation by that 
before activation. (c) The ratio of the change in the cell capacitance, a measure of the cell body size and 
conductance, was calculated by dividing the average capacitance after activation by that before 
activation. (d) The ratio of the change in series resistance was calculated by dividing the average 
capacitance after activation by that before activation. (e) The ratio of the change in EPSC amplitude after 
inactivation. (f) The ratio of the change in EPSC charge after inactivation (g) The ratio of the change in 
cell capacitance after inactivation. (h) The ratio of the change in series resistance after inactivation. Error 
bars were calculated as s.e.m.; ns = not significant P>0.05, **P<0.01, ***P<0.001. 
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Supplementary Figure 14 | PhoDAG-3 modulates synaptic transmission in hippocamcal neurons. 
WT mouse hippocampal neurons were pre-incubated at 37 ºC in the extracellular recording solution 
containing 500 M PhoDAG-3 or DMSO. The neurons were then whole-cell voltage clamped at room 
temperature and stimulated at 0.2 Hz. The evoked EPSCs were monitored. (a) The initial EPSC 
amplitudes measured in control neurons (black, n = 12) or in neurons where trans-PhoDAG-3 was 
applied (red, n = 13) are not significantly different. (b) The normalized EPSC amplitude is plotted for two 
neurons preincubated with PhoDAG-3 (red) and for two control neurons (black). (c) Example traces of 
EPSCs during activation and inactivation for PhoDAG-3. (d) Activation and inactivation by PhoDAG-3 
could be repeated over several cycles, corresponding to an increase and decrease in the EPSC 
amplitude, respectively (red = PhoDAG-3, n = 13; black = vehicle, n = 12). (e) The sEPSC frequency 
could also be increased by photoactivation with UV-A light, and decreased by inactivation with blue light 
(red = PhoDAG-3, n=11; black = vehicle, n=10). Data from individual neurons are presented by open 
circles, summaries are presented as mean ± s.e.m. The Mann-Whitney test was used to determine 
statistical significance. ns = not significant P>0.05.  
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SUPPLEMENTARY NOTES 
 
 
Supplementary Note 1 | Synthesis and characterization of a short-chain photoswitchable fatty 
acid. (a) The chemical synthesis of FAAzo-9 (4). (b) UV-Vis spectroscopy showed that FAAzo-9 (50 M 
in DMSO) could be isomerized between its cis- and trans-configurations with UV-A and blue light, 
respectively. Absorption spectra are shown for the dark-adapted (black), UV-adapted (grey) and blue-
adapted (blue) photostationary states. 
19 
 
 
Supplementary Note 2 | Synthesis and characterization of the photoswitchable diacylglycerols. 
(a) PhoDAG-1 was synthesized in four steps and 57% overall yield. (b) A representative NMR spectrum 
of PhoDAG-1 (in CDCl3), displaying the aromatic region. Both the trans- and cis- azobenzene protons 
give signals under ambient lighting conditions, where PhoDAG-1 exists as 10% the cis-isomer. (c) The 
chemical syntheses of the short-chain photoswitchable DAGs, PhoDAG-2 and PhoDAG-3. 
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Supplementary Note 3 |Synthetic Procedures 
Synthesis of S-2,3-O-isopropylidene-1-O-stearoyl-sn-glycerol (6) 
 
S-2,3-O-Isopropylidene-1-O-stearoyl-sn-glycerol (6) was prepared using a modified procedure as 
previously described by Gaffney et al.
67
 Spectral characteristics matched those previously reported
68
. 
R(-)-2,3-O-Isopropylidene-sn-glycerol (2.85 g, 22.0 mmol, 1.0 equiv.) and 4-(dimethylamino)pyridine 
(DMAP, 268 mg, 2.20 mmol, 0.1 equiv.) were dissolved in dry CH2Cl2 (75 mL) under an argon 
atmosphere. To this solution was added dry NEt3 (6.16 mL, 4.48 g, 44.0 mmol, 2.0 equiv.) and the 
reaction was cooled to 0 C. Stearoyl chloride was dissolved in dry CH2Cl2 (25 mL) and slowly added to 
the previously prepared solution. The reaction was allowed to slowly warm to room temperature and 
stirred for 2 h. H2O (28 mL) was slowly added and the biphasic solution was stirred rapidly for 10 min. The 
phases were then separated, and the organic phase was washed with aqueous HCl (2 M, 50 mL), 
followed by saturated aqueous NaHCO3 (2x50 mL) and brine (2x50 mL) solutions. The organic phase 
was then dried over anhydrous Na2SO4 and filtered. The filtrate was then concentrated and purified by 
flash silica gel chromatography (150 g SiO2, 20:1 hexane:EtOAc) to yield S-2,3-O-isopropylidene-1-O-
stearoyl-sn-glycerol (6, 6.99 g, 81%) as an off-white solid. 
 
TLC (20:1 hexanes:EtOAc): Rf = 0.25.  
1
H NMR (CDCl3, 400 MHz, 25 C): δ 4.35–4.28 (m, 1 H, H2G), 4.17 (dd, 1 H, HG1a, J = 11.7, 4.7 Hz), 
4.12–4.05 (m, 2 H, HG1b, HG3a), 3.75 (dd, 1H, H3b, J = 8.4, 6.2 Hz) 2.34 (t, 2 H, H2La,b, J = 7.4 Hz), 
1.67–1.58 (m, 2 H, H3La,b), 1.43 (s, 3 H, HCH3), 1.37 (s, 3 H, HCH3), 1.33–1.21 (m, 28 H, Halk), 0.87 (t, 3 H, 
H8La,b,c, J = 6.5 Hz). 
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Synthesis of 1-O-stearoyl-3-O-triethylsilyl-sn-glycerol (7) 
 
1-O-stearoyl-3-O-triethylsilyl-sn-glycerol (7) was prepared using a modified procedure as previously 
described by Nadler et al.
15
 Spectral characteristics matched those previously reported. 
 
S-2,3-O-Isopropylidene-1-O-stearoyl-sn-glycerol (6, 500 mg, 1.25 mmol, 1.0 equiv.) was dissolved in 
dry 1,2-dichloroethane (DCE, 20 mL) under an argon atmosphere. N,N-Diisopropylethylamine (DIPEA, 
1.20 mL, 6.88 mmol), followed by triethylsilyl trifluoromethanesulfonate (TESOTf, 496 mg, 0.425 mL, 
1.88 mmol, 1.5 equiv.) were added at room temperature and the reaction was stirred at 90 C. After 1 h, a 
second portion of TESOTf (169 mg, 0.145 mL, 0.5 equiv.) was added and the reaction was stirred at 
90 C for 2.5 h. Upon consumption of the starting material as determined by TLC analysis, the solution 
was cooled to room temperature, diluted with EtOAc, and then washed with aqueous hydrochloric acid 
(0.1 M, 50 mL) and brine (50% saturated, 2x50 mL). The organic phase was concentrated under reduced 
pressure and the resulting oil was dissolved in THF (20 mL). To this solution was added an aqueous 
Na2CO3 solution (10%, 10 mL) followed by I2 (610 mg, 2.4 mmol, 1.95 equiv.). The solution was stirred 
rapidly for 2.5 h at room temperature. A further portion of I2 was added (300 mg, 1.2 mmol, 1.0 equiv.) and 
the solution was stirred at room temperature for 1 h. The solution was diluted with EtOAc (50 mL) and 
washed with saturated aqueous Na2S2O3 (50 mL), water (2x50 mL) and brine (50 mL) solutions. The 
organic phase was then dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated 
under reduced pressure and the resulting oil was purified by flash column chromatography (50 g SiO2, 
20:1 hexanes:EtOAc) to yield 1-O-stearoyl-3-O-triethylsilyl-sn-glycerol (7, 412 mg, 69%) as a colorless 
liquid. 
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TLC (10:1 hexanes:EtOAc): Rf = 0.23.  
1
H NMR (CDCl3, 400 MHz, 25 C):  4.18 (m, 2 H, H1Ga,b), 3.92–3.82 (m, 1 H, H2G), 3.67 (dd, 1 H, 
H3Ga, J = 10.3 Hz, 4.5 Hz), 3.60 (dd, 1 H, H3Gb, J = 10.0 Hz, 5.7 Hz), 2.55 (d, 1 H, OH, J = 5.3 Hz), 2.33 
(t, 2 H, H2Sa,b, J = 7.6 Hz), 1.66–1.58 (m, 2 H, H3Sa,b), 1.34–1.20 (m, 28 H, 14xCH2(stearoyl)), 0.96 (t, 9 H, 
3xCH3(TES), J = 7.8 Hz), 0.88 (t, 3 H, H18Sa,b,c, J = 6.9 Hz), 0.61 (q, 6 H, 3xCH2(TES), J = 7.9 Hz).  
13
C NMR (CDCl3, 100 MHz, 25 C):  174.1 (C1S), 70.2 (C2G), 65.1 (C1G), 63.5 (C3G), 34.3 (C2S), 32.1 
(Calk), 29.9-29.7 (m, Calk), 29.6 (Calk), 29.5 (Calk), 29.4 (Calk), 29.3 (Calk), 25.1 (C3S), 22.9 (Calk), 14.3 
(C18S), 6.8 (3C, 3xCH3(TES)), 4.4 (3C, 3xCH2(TES)).  
HRMS (ESI
+
): m/z calcd. for [C27H56NaO4Si]
+
: 495.3846, found: 495.3850 ([M+Na]
+
). 
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Synthesis of 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-3-O-triethylsilyl-sn-
glycerol (8) 
 
FAAzo-4
19
 (1.08 g, 3.3 mmol, 2.0 equiv.), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC, 773 mg, 
4.38 mmol, 3.0 equiv.) and DMAP (20.2 mg, 166 mol, 0.1 equiv.) were dissolved in dry CH2Cl2 (50 mL) 
under an argon atmosphere. This solution was stirred at room temperature for 15 min. After cooling to 
0 C, a solution of 1-O-stearoyl-3-O-triethylsilyl-sn-glycerol (7, 787 mg, 1.66 mmol, 1.0 equiv.) in dry 
CH2Cl2 (30 mL) was slowly added. The solution was warmed to room temperature and stirred overnight 
under an argon atmosphere. The solution was then diluted with CH2Cl2 (200 mL) and washed with water 
(2x100 mL) and brine (100 mL). The solution was then filtered and the filtrate was concentrated under 
reduced pressure. The resulting red oil was purified by flash silica gel chromatography (170 g SiO2, 30:1 
hexanes:EtOAc) to yield 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-3-O-
triethylsilyl-sn-glycerol (8, 944 mg, 72%) as a red oil. 
 
  
24 
 
TLC (10:1 hexanes:EtOAc): Rf = 0.50.  
1
H NMR (CDCl3, 400 MHz, 25 C):  7.85–7.80 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, H13Aa,b, 
J = 8.2 Hz), 5.13–5.05 (m, 1 H, H2G), 4.38 (dd, 1 H, H1Ga, J = 12.1 Hz, 3.6 Hz), 4.17 (dd, 1 H, H1Gb, 
J = 12.1 Hz, 6.1 Hz), 3.73 (d, 2 H, H3Ga,b, J = 5.3 Hz), 2.73 (t, 2 H, H4Aa,b, J = 7.7 Hz), 2.69 (t, 2 H, 
H15Aa,b, J = 7.8 Hz), 2.37 (t, 2 H, H2Aa,b, J = 7.5 Hz), 2.29 (t, 2 H, H2Sa,b, J = 7.6 Hz), 2.00 (quin, 2 H, 
H3Aa,b, J = 7.4 Hz), 1.69–1.53 (m, 4 H, H3Sa,b, H16Aa,b), 1.43–1.34 (m, 2 H, H17Aa,b), 1.33–1.21 (m, 28 H, 
H17Sa,b, 13xCH2(Stear)), 0.97–0.85 (m, 15 H, H18Aa,b,c, H17Sa,b,c, 3xCH3(TES)), 0.59 (q, 6 H, 3xCH2(TES), 
J = 8.0 Hz). 
13
C NMR (CDCl3, 100 MHz, 25 C):  173.7 (C1S), 172.8 (C1A), 151.4 (CAzo), 151.1 (CAzo), 146.5 (CAzo), 
144.6 (CAzo), 129.3 (2 C, CAzo), 129.2 (2 C, CAzo), 123.0 (2 C, CAzo), 122.9 (2 C, CAzo), 72.1 (C2G), 
62.6 (C3G), 61.3 (C1G), 35.7 (C15A), 35.0 (C4A), 34.3 (C2S), 33.7 (C2A), 33.6 (C2S), 32.1 (C3S), 
29.9-29.7 (m, CAlk), 29.6 (CAlk), 29.5 (CAlk), 29.4 (CAlk), 29.3 (CAlk), 26.5 (C3A), 25.1 (C16A), 22.9 (C17S), 
22.5 (C17A), 14.3 (C18S), 14.1 (C18A), 6.8 (3 C, 3xCH3(TES)), 4.4 (3 C, 3xCH2(TES)).  
HRMS (EI
+
): m/z calcd. for [C20H24N2O2]
+
: 778.5680, found: 778.5675 ([M-e
-
]
+
). 
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Synthesis of 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-sn-glycerol 
(PhoDAG-1, 1) 
 
2-O-(4-(4-((4-Butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-3-O-triethylsilyl-sn-glycerol 
(8, 500 mg, 0.641 mmol, 1.0 equiv.) was first dissolved in CH2Cl2 (5 mL) and added to a solution of 
FeCl2·6H2O (5 mM in 25 mL 3:1 MeOH:CH2Cl2). This solution was stirred at room temperature for 30 min. 
The solution was then diluted with EtOAc (200 mL) and washed with water (2x200 mL). The organic 
phase was then dried over Na2SO4. The mixture was filtered and the filtrate was concentrated under 
reduced pressure. The resulting oil was purified by flash silica gel chromatography (3:1 hexanes:EtOAc) 
to yield 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-sn-glycerol (PhoDAG-1, 
0.425 mg, quant.) as an orange solid. Note: Short reaction times and quick chromatography are essential 
to avoid acyl chain migration. 
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TLC (3:1 hexanes:EtOAc): Rf = 0.45 (trans), 0.35 (cis).  
1
H NMR (CDCl3, 400 MHz, 25 C):  7.85–7.80 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, H13Aa,b, 
J = 8.1 Hz), 5.10 (quin, 1 H, H2G, J = 5.1 Hz), 4.34 (dd, 1 H, H3Ga, J = 11.9 Hz, 4.5 Hz), 4.24 (dd, 1 H, 
H3Gb, J = 12.0 Hz, 5.8 Hz), 3.73 (t, 2 H, H1Ga,b, J = 5.2 Hz), 2.74 (t, 2 H, H4Aa,b, J = 7.6 Hz), 2.69 (t, 2 H, 
H15Aa,b, J = 7.6 Hz), 2.40 (t, 2 H, H2Aa,b, J = 7.3 Hz), 2.32 (t, 2 H, H2Sa,b, J = 7.5 Hz), 2.06–1.97 (m, 2 H, 
H3Aa,b), 1.69–1.51 (m, 4 H, H16Aa,b, H3Sa,b), 1.44–1.32 (m, 2 H, H17Aa,b), 1.34–1.18 (m, 28 H, H17Sa,b, 
28xHSAlk), 0.94 (t, 3 H, H18Aa,b,c, J = 7.1 Hz), 0.88 (t, 3 H, H18Sa,b,c, J = 7.1 Hz).  
13
C NMR (CDCl3, 100 MHz, 25 C):  174.0 (C1S), 173.1 (C1A), 151.5 (CAzo), 151.1 (CAzo), 146.5 (CAzo), 
144.4 (CAzo), 129.3 (2 C, CAzo), 129.2 (2 C, CAzo), 123.0 (2 C, CAzo), 122.9 (2 C, CAzo), 72.4 (C2G), 62.1 
(C3G), 61.6 (C1G), 35.7 (C15A), 35.0 (C4A), 34.2 (C2S), 33.6 (C2A), 33.6 (C3S), 29.9-29.7 (m, CAlk), 
29.6 (CAlk), 29.5 (CAlk), 29.4 (CAlk), 29.3 (CAlk), 26.4 (C3A), 25.0 (C16A), 22.9 (C17S), 22.5 (C17A), 14.3 
(C18S), 14.1 (C18A).  
IR (neat, ATR): ṽ = 3483, 2955, 2917, 2850, 1728, 1711, 1601, 1499, 1472, 1460, 1414, 1379, 1256, 
1235, 1214, 1188, 1173, 1138, 1096, 1068, 1052, 1031, 1012, 962, 888, 832, 718, 679.  
HRMS (EI
+
): m/z calcd. for [C20H24N2O2]
+
: 324.1838, found: 324.1834 ([M-e
-
]
+
).  
UV-Vis (25 M in DMSO): max(-*) = 340 nm. max(n-*) = 442 nm (Fig. 1e). 
Melting point (C): 66.5–67.2. 
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Synthesis of S-2,3-O-isopropylidene-1-O-octanoyl-sn-glycerol (9) 
 
Octanoic acid (490 mg, 3.4 mmol, 1.5 equiv.) was first dissolved in dry CH2Cl2 (10 mL) under an argon 
atmosphere and then NEt3 (0.310 mL, 2.27 mmol, 1 equiv.) and DMAP (27.7 mg, 0.227 mmol, 0.1 equiv.) 
were added. The solution was then cooled to 0 °C and then N,N'-dicyclohexylcarbodiimide (DCC, 
1.171 mg, 5.68 mmol, 2.5 equiv.) was added. This mixture was stirred at 0 °C for 30 min and then the 
R(-)-2,3-O-Isopropylidene-sn-glycerol (0.280 mL, 2.27 mmol, 1.0 equiv.) was added. The solution was 
stirred for a further 2 h, and then was diluted with CH2Cl2 and washed once with a saturated aqueous 
NaHCO3  solution, and twice with H2O. The organic phase was then dried over Na2SO4 and filtered. The 
filtrate was concentrated under reduced pressure and the resulting oil was purified by flash silica gel 
chromatography (30 g SiO2, pre-adsorbed on 1.5 g of SiO2, 40:1 to 10:1 hexanes:EtOAc) to yield S-2,3-
O-isopropylidene-1-O-octanoyl-sn-glycerol (9, 537.3 mg, 92%) as a colorless oil. 
 
TLC (20:1 hexanes:EtOAc): Rf = 0.09.  
1
H NMR (CDCl3, 400 MHz, 25 C): δ 4.32–4.24 (m, 1 H, H2G), 4.17–4.09 (m, 1 H, HG1a), 4.09–4.00 (m, 
2 H, HG1b, HG3a), 3.73–3.68 (m, 1H, H3b) 2.31 (t, 2 H, H2La,b, J = 7.3 Hz), 1.65–1.54 (m, 2 H, H3La,b), 
1.40–1.33 (s, 6 H, 2xHCH3), 1.31–1.17 (m, 8 H, Halk), 0.84 (t, 3 H, H8La,b,c, J = 6.7 Hz). 
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Synthesis of 1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (10) 
 
S-2,3-O-isopropylidene-1-O-octanoyl-sn-glycerol (9, 453.2 mg, 1.75 mmol, 1.0 equiv.) was first 
dissolved in dry 1,2-dichloroethane (6 mL) under an argon atmosphere and then dry 
N,N-diisopropylethylamine (DIPEA , 1.5 mL, 9.65 mmol , 5.5 equiv.) was added to the solution. The 
solution was then warmed to 90 °C and TESOTf (1.4 mL, 6.13 mmol, 3.5 equiv.) was added and the 
reaction stirred for 2 h. The mixture was then diluted with EtOAc (60 mL) and washed with aqueous HCl 
(0.1 M, 60 mL) and then H2O (2x60 mL). The organic phase was then dried over Na2SO4 and filtered. The 
filtrate was concentrated under reduced pressure. The resulting oil was dissolved in THF (8 mL) and then 
aqueous Na2CO3 (4 mL, 10% w/w) and I2 (1.110 g, 4.38 mmol, 2.5 equiv.) were added to the solution. The 
reaction was stirred for 75 min at room temperature, and was then diluted with EtOAc (70 mL) and 
washed once with saturated aqueous Na2S2O3 (70 mL) and H2O (2x70 mL). The organic phase was dried 
over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure and the resulting oil was 
purified by flash silica gel chromatography (60 g SiO2, 20:1→15:1→10:1 hexanes:EtOAc) to yield 1-O-
octanoyl-3-O-triethylsilyl-sn-glycerol (10, 211 mg, 36%) as a colourless oil. 
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TLC (9:1 hexanes:EtOAc): Rf = 0.30.  
1
H NMR (CDCl3, 400 MHz, 25 C): δ 4.19–4.08 (m, 2 H, H1Ga,b), 3.98–3.87 (m, 1 H, H2G), 3.63 (dd, 1 H, 
H3Ga, J1 = 10.5 Hz, J2 = 5.3 Hz), 3.56 (dd, 1 H, H3Gb, J1 = 10.3 Hz, J2 = 5.4 Hz), 2.69 (d, 1 H, OH, 
J = 5.4 Hz), 2.34 (t, 2 H, H2a,b, J = 7.5 Hz), 1.67–1.58 (m, 2 H, H3a,b), 1.34–1.20 (m, 8 H, Halk), 0.96 (t, 9 
H, 3xCH3(TES), J = 7.9 Hz), 0.87 (t, 3 H, H8a,b,c, J = 6.9 Hz), 0.61 (q, 6 H, 3xCH2(TES), J = 7.9 Hz). 
13
C NMR (CDCl3, 100 MHz, 25 C): δ 174.1 (C1L), 70.2 (CXG), 65.1 (CXG), 63.5 (CXG), 34.3 (C2), 31.8 
(Calk), 29.2 (Calk), 29.1 (Calk), 25.1 (Calk), 22.8 (C7L), 14.2 (C8L), 6.8 (3C, 3xCH3(TES)), 4.4 (3C, 3xCH2(TES)). 
IR (neat, ATR): ṽ = 3489, 2955, 2929, 2876, 1740, 1458, 1416, 1380, 1239, 1166, 1100, 1006, 976, 842, 
807, 744, 728, 676, 619, 588, 601, 564. 
HRMS (ESI
+
): m/z calcd. for [C17H37O4Si]
+
: 333.2461, found: 333.2460 ([M+H
+
]
+
). 
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Synthesis of 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-
glycerol (11) 
 
FAAzo-4
19
 (136.3 mg, 0.42 mmol, 2.0 equiv.) was dissolved in dry CH2Cl2 (12 mL) under an argon 
atmosphere, and then DMAP (5.13 mg, 0.042 mmol, 0.1 equiv.) and EDC (0.11 mL, 0.63 mmol, 3.0 
equiv.) were added. The solution was stirred at room temperature for 20 min and then 1-O-octanoyl-3-O-
triethylsilyl-sn-glycerol (10, 68.9 mg, 0.21 mmol, 1.0 equiv.) was added. The solution was stirred 
overnight at room temperature, diluted with CH2Cl2  and then washed three times with H2O. The organic 
phase was dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The 
resulting dark orange oil was purified by flash silica gel chromatography (15 g SiO2, hexanes:EtOAc 
20:1→10:1) to yield 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-
triethylsilyl-sn-glycerol (11, 77.4 mg, 58%) as an orange oil. 
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TLC (3:1 hexanes:EtOAc): Rf = 0.48 (trans), 0.30 (cis).  
1
H NMR (CDCl3, 400 MHz, 25 C): δ 7.87–7.79 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, H13Aa,b, 
J = 8.7 Hz), 5.14–5.05 (m, 1 H, H2G), 4.42–4.33 (m, 1H, H1Ga), 4.23–4.13 (m, 1 H, H1Gb), 3.77–3.69 (m, 
2 H, H3Ga,b), 2.78–2.67 (m, 4 H, H4Aa,b, H15Aa,b), 2.37 (t, 2 H, H1Aa,b, J = 7.1 Hz), 2.30 (t, 2 H, H2La,b, 
J = 7.3 Hz), 2.07–1.95 (m, 2 H, H3Aa,b), 1.69–1.52 (m, 4 H, H3La,b, H16Aa,b), 1.44–1.33 (m, 2 H , 
H17Aa,b), 1.33–1.19 (m, 8 H, Halk), 0.99–0.90 (m, 12 H, H18Aa,b,c, 3xCH3(TES)), 0.86 (t, 3 H, H8La,b,c), 0.59 
(q, 6 H, 3xCH2(TES), J = 8.0 Hz).  
13
C NMR (CDCl3, 100 MHz, 25 C): δ 173.6 (C1S), 172.8 (C1A), 151.4 (CAzo), 151.9 (CAzo), 146.4 (CAzo), 
144.6 (CAzo), 129.3 (2 C, CAzo), 129.2 (2 C, CAzo), 123.0 (2 C, CAzo),  122.9 (2 C, CAzo), 72.1 (C2G), 62.6 
(C3G), 61.3 (C1G), 35.7 (C15A), 35.0 (C4A), 34.3 (C2A), 33.63 (C2A), 33.59 (C3A), 31.8 (C3L), 29.2 
(CAlk), 29.1 (CAlk), 26.5 (CAlk), 25.0 (CAlk), 22.7 (CAlk), 22.5 (CAlk), 14.2 (C18L), 14.1 (C18A), 6.8 (3 C, 
3xCH3(TES)), 4.4 (3 C, 3xCH2(TES)). 
IR (neat, ATR): ṽ = 3028, 2955, 2930, 2874, 2859, 1918, 1739, 1602, 1580, 1498, 1458, 1416, 1378, 
1302, 1240, 1226, 1156, 1145, 1104, 1013, 977, 844, 800, 744, 728, 674, 642, 618, 601, 571, 564. 
HRMS (ESI
+
): m/z calcd. for [C37H59N2O5Si]
+
: 639.4193, found: 639.4142 ([M+H
+
]
+
). 
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Synthesis of 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-octanoyl-sn-glycerol 
(PhoDAG-2, 2) 
 
2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-octanoyl-sn-glycerol (PhoDAG-2) was 
prepared from 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-
glycerol (7, 28.0 mg, 0.044 mmol, 1.0 equiv.) as described above in the synthesis of 2-O-(4-(4-((4-
butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-sn-glycerol (PhoDAG-1). PhoDAG-2 (13.3 mg, 
66%) was isolated as an orange oil. NOTE: all reactants and reagents were scaled according to molarity. 
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TLC (2:1 hexanes:EtOAc): Rf : 0.39 (trans), 0.28 (cis). 
1
H NMR (CDCl3, 400 MHz, 25 C): δ 7.86–7.79 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, H13Aa,b, 
J = 8.7 Hz), 5.15–5.05 (m, 1 H, H2G), 4.37–4.30 (m, 1H, H3Ga), 4.27–4.20 (m, 1 H, H3Gb), 3.76–3.70 (m, 
2 H, H1Ga,b), 2.74 (t, 2 H, H4Aa,b, J = 7.5 Hz), 2.69 (t, 2 H, H15Aa,b, J = 7.8 Hz), 2.40 (t, 2 H, H2Aa,b, 
J = 7.5 Hz), 2.36–2.29 (m, 2 H, H2La,b), 2.07–1.97 (m, 3 H, H3Aa,b), 1.70–1.50 (m, 4 H, H16Aa,b, HL3a,b), 
1.44–1.18 (m, 10 H, Halk), 0.93 (t, 3 H, H18Aa,b,c, J = 7.3 Hz), 0.90–0.81 (t, 3 H, H8La,b,c, J = 7.6 Hz). 
13
C NMR (CDCl3, 100 MHz, 25 C): δ 174.0 (C1L), 173.0 (C1A), 152.8 (CAzo), 151.3 (CAzo), 146.5 (CAzo),  
144.4 (CAzo), 129.3 (2 C, CAzo), 129.2 (2 C, CAzo), 123.9 (2 C, CAzo), 122.9 (2 C, Cazo), 72.4 (C2G), 62.1 
(C3G), 61.6 (C1G), 35.7 (C15A), 35.0 (C4A), 34.2 (C2L), 33.61 (CAlk), 33.58 (CAlk), 31.8 (CAlk), 29.2 (CAlk), 
29.1 (CAlk), 26.4 (C3A), 25.0 (C3L), 22.7 (C7L), 22.5 (C17A), 14.2 (C8L), 14.1 (C18A). 
IR (neat, ATR): ṽ = 3466, 2956, 2929, 2858, 1739, 1602, 1498, 1458, 1417, 1378, 1225, 1159, 1103, 
1051, 1014, 844, 728, 634, 614, 591, 576, 568. 
HRMS (EI
+
): m/z calcd. for [C31H44N2O5]
+
: 524.3250, found: 524.3245 ([M-e
-
]
+
). 
UV-Vis (50 µM in DMSO): max(–*) =  340 nm. max(n–*) = 440 nm. 
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Synthesis of 4-(Phenyldiazenyl)phenyl butanoic acid  (FAAzo-9, 4) 
 
4-(4-aminophenyl)butyric acid (200 mg, 1.12 mmol, 1.0 equiv.) was first dissolved in CH2Cl2 (20 mL). 
Nitrosobenzene (143.4 mg, 1.34 mmol, 1.2 equiv.) and AcOH (5 mL) were added, and the solution was 
then stirred at room temperature overnight. The solvents were then removed under reduced pressure. 
The resulting crude residue was purified by flash silica gel chromatography (20 g SiO2, 99:1 
CH2Cl2:AcOH) to yield 4-(phenyldiazenyl)phenyl butanoic acid (FAAzo-9, 320.8 mg, quant.) as an 
orange solid. 
 
TLC (99:1 CH2Cl2:AcOH): Rf = 0.17. 
1
H NMR (CDCl3, 400 MHz, 25 C): δ 7.94–7.82 (m, 4 H, H7a,b, H11a,b), 7.55–7.43 (m, 3 H, H13a,b, H14), 
7.34 (d, 2 H, H6a,b, J = 4.0 Hz), 2.76 (t, 2 H, H4a,b, J = 7.8 Hz), 2.42 (t, 2 H, H2a,b, J = 7.3 Hz), 2.02 (dd, 2 
H, H3a,b, J = 7.8, 7.3 Hz). 
13
C NMR (CDCl3, 100 MHz, 25 C): δ 178.7 (C1), 152.8 (C11), 151.4 (C8), 144.8 (C5), 131.0 (C14), 
129.4-129.2 (4 C, C6a,b, C13a,b), 123.2-122.9 (4 C, C7a,b, C12a,b), 35.0 (C4), 33.2 (C2), 26.2 (C3). 
IR (neat, ATR): ṽ = 3041, 2944, 1693, 1601, 1500, 1486, 1462, 1439, 1411, 1339, 1303, 1282, 1252, 
1215, 1152, 1106, 1071, 1020, 914, 851, 822, 787, 764, 745, 732, 684, 638, 616, 577, 561. 
HRMS (EI
+
): m/z calcd. for [C16H16N2O2]
+
: 268.1212, found: 268.1206 ([M-e
-
]
+
). 
UV-Vis (50 M in DMSO): max(–*) =  330 nm. max(n–*) = 425 nm. 
Melting point (C): 135.5–137.5.  
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Synthesis of 2-O-(4-(4-(phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-glycerol 
(12)  
 
4-(Phenyldiazenyl)phenyl butanoic acid (FAAzo-9, 153.4 mg, 0.57 mmol, 2.0 equiv.) was dissolved in 
dry CH2Cl2 (15 mL) under an argon atmosphere. DMAP (3.4 mg, 0.028 mmol, 0.1 equiv.) and 
EDC (0.15 mL, 0.84 mmol, 3.0 equiv.) were then added to the solution. The mixture was stirred at room 
temperature for 20 min and then 1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (10, 95.1 mg, 0.28 mmol, 
1.0 equiv.) was added. The solution was stirred overnight at room temperature, and was then diluted with 
CH2Cl2 (100 mL) and washed with H2O (3x50 mL). The organic phase was dried over Na2SO4 and then 
filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel 
chromatography (20 g SiO2, hexanes:ethyl acetate 20:1→10:1) to yield 2-O-(4-(4-
(phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (12, 100 mg, 61%) as 
an orange oil. 
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TLC (9:1 hexanes:EtOAc): Rf =  0.43 (trans),  0.25 (cis).  
1
H NMR (CDCl3, 400 MHz, 25 C): δ 7.94–7.83 (m, 4 H, H7Aa,b, H12Aa,b), 7.55–7.43 (m, 3 H, H14A, 
H13Aa,b), 7.33 (d, 2 H, H6Aa,b, J = 8.2 Hz), 5.15–5.05 (m, 1 H, H2G), 4.41–4.33 (m, 1H, H1Ga), 4.22–4.13 
(m, 1 H, H1Gb), 3.78–3.69 (m, 2 H, H3Ga,b), 2.74 (t, 2 H, H4Aa,b, J = 7.2 Hz), 2.38 (t, 2 H, H2A, 
J = 7.6 Hz), 2.30 (t, 2 H, H2La,b, J = 7.5 Hz), 2.08–1.96 (m, 2 H, H3Aa,b), 1.64–1.54 (m, 2 H, H3La,b), 1.34–
1.19 (m, 8 H, HAlk), 0.94 (t, 9 H, 3xCH3(TES), J = 8.3 Hz), 0.90–0.82 (t, 3 H, H8La,b,c, J = 6.9 Hz), 0.59 (m, 
6 H, 3xCH2(TES), J = 8.2 Hz). 
13
C NMR (CDCl3, 100 MHz, 25 C): δ 173.6 (C1L), 172.8 (C1A), 152.8 (CAzo), 151.3 (CAzo), 
145.0 (CAzo), 131.0 (CAzo), 129.3 (2C, CAzo), 129.2 (2 C, CAzo), 123.1 (2 C, CAzo), 122.9 (2 C, CAzo), 72.1 
(C2G), 62.6 (C3G), 61.3 (C1G), 35.0 (C4A), 34.3 (C2L), 33.6 (C2A), 31.8 (CAlk), 29.2 (CAlk), 29.1 (CAlk), 
26.5 (CAlk), 25.0 (CAlk), 22.7 (C7L), 14.2 (C8L), 6.8 (3 C, 3xCH3(TES)), 4.4 (3 C, 3xCH2(TES)). 
IR (neat, ATR): ṽ = 2955, 2930, 2875, 1738, 1603, 1500, 1458, 1415, 1378, 1300, 1240, 1225, 1144, 
1103, 1070, 1004, 847, 797, 743, 727, 688, 638, 616, 598, 563. 
HRMS (ESI
+
): m/z calcd. for [C33H51N2O5Si]
+
: 583.3567, found: 583.3567 ([M+H
+
]
+
). 
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Synthesis of 2-O-(4-(4-(phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-sn-glycerol (PhoDAG-3, 3) 
 
2-O-(4-(4-(phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-sn-glycerol (PhoDAG-3) was prepared 
from 2-O-(4-(4-(phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (8, 
22.0 mg, 0.038 mmol, 1 equiv.) as described above in the synthesis of 2-O-(4-(4-((4-
butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-sn-glycerol (PhoDAG-1). PhoDAG-3 (17.7 mg, 
quant.) was isolated as an orange oil. NOTE: all reactants and reagents were scaled according to 
molarity. 
TLC (9:1 hexanes:ethyl acetate): Rf = 0.20 (trans),  0.18 (cis).  
1
H NMR (CDCl3, 400 MHz, 25 C): δ 7.93–7.83 (m, 4 H, H7Aa,b, H11Aa,b), 7.55–7.43 (m, 3 H, H14A, 
H13Aa,b), 7.33 (d, 2 H, H6Aa,b, J = 8.3 Hz), 5.14–5.04 (q, 1 H, H2G, J = 4.9 Hz), 4.38–4.29 (m, 1 H, H3Ga), 
4.27–4.19 (m, 1 H, H3Gb), 3.78–3.68 (m, 2 H, H1Ga,b), 2.75 (t, 2 H, H4Aa,b, J = 7.7 Hz), 2.40 (t, 2 H, 
H2Aa,b, J = 7.7 Hz), 2.32 (t, 2 H, H2La,b, J = 7.7 Hz), 2.07–1.96 (m, 2 H, H3Aa,b), 1.65–1.55 (m, 2 H, 
H3La,b), 1.34–1.20 (m, 8 H, Halk), 0.90–0.82 (t, 3 H, H8La,b,c, J = 7.1 Hz). 
13
C NMR (CDCl3, 100 MHz, 25 C): δ 173.4 (C1L), 173.0 (C1A), 152.8 (CAzo), 151.3 (CAzo), 144.8 (CAzo), 
130.9 (CAzo), 129.3 (2 C, CAzo), 129.2 (2 C, CAzo), 123.2 (2 C, CAzo), 122.9 (2 C, CAzo), 72.4 (C2G), 62.1 
(C3G), 61.6 (C1G), 35.0 (C4A), 34.2 (C2L), 33.6 (2 C, C2A, C14A), 31.8 (C6L), 29.2 (CAlk), 29.0 (CAlk), 
26.4 (CAlk), 25.0 (CAlk), 22.7 (C7A), 14.2 (C8A). 
IR (neat, ATR): ṽ =3466, 2928, 2857, 1739, 1603, 1458, 1416, 1377, 1224, 1157, 1104, 1052, 847, 768, 
690, 615, 601, 590, 568, 554. 
HRMS (EI
+
): m/z calcd. for [C27H36N2O5]
+
: 468.2624, found: 468.2622 ([M-e
-
]
+
). 
UV-Vis (50 M in DMSO): max(-*) =  325 nm. max(n-*) = 440 nm. 
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NMR SPECTRA 
 
 
 
Supplementary Note 4 | 
1
H- and 
13
C-NMR spectra of 1-O-stearoyl-3-O-triethylsilyl-sn-glycerol (7). 
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Supplementary Note 5 | 
1
H- and 
13
C-NMR spectra of 2-O-(4-(4-((4-butylphenyl)diazenyl) 
phenyl)butanoyl)-1-O-stearoyl-3-O-triethylsilyl-sn-glycerol (8). 
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Supplementary Note 6 | 
1
H- and 
13
C-NMR spectra of 2-O-(4-(4-((4-butylphenyl)diazenyl) 
phenyl)butanoyl)-1-O-stearoyl-sn-glycerol (PhoDAG-1, 1). 
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Supplementary Note 7 | 
1
H- and 
13
C-NMR spectra of  4-(Phenyldiazenyl)phenyl butanoic acid (FAAzo-9, 
4). 
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Supplementary Note 8 | 
1
H- and 
13
C-NMR spectra of 1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (10). 
 
43 
 
 
 
Supplementary Note 9 | 
1
H- and 
13
C-NMR spectra of 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl) 
butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (11). 
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Supplementary Note 10 | 
1
H- and 
13
C-NMR spectra of 2-O-(4-(4-((4-butylphenyl)diazenyl) 
phenyl)butanoyl)-1-O-octanoyl-sn-glycerol (PhoDAG-2, 2). 
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Supplementary Note 11 | 
1
H- and 
13
C-NMR spectra of 2-O-(4-(4-(phenyldiazenyl)phenyl)butanoyl)-1-O-
octanoyl-3-O-triethylsilyl-sn-glycerol (12). 
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Supplementary Note 12 | 
1
H- and 
13
C-NMR spectra of 2-O-(4-(4-(phenyldiazenyl) 
phenyl)butanoyl)-1-O-octanoyl-sn-glycerol (PhoDAG-3, 3). 
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Supplementary Movie 1 | PhoDAG-1 enabled optical control of PKC-RFP translocation. A 
representative stack of fluorescence images showing PKC-RFP fluorescence in HeLa cells transiently 
expressing the reporter. The application of PhoDAG-1 (red circle, 100 M) did not affect the localization 
of PKC-RFP. On  = 375 nm irradiation, PKC-RFP translocated to the plasma membrane. After the 
termination of irradiation, PKC-RFP diffused back to the cytoplasm. This effect could be repeated over 
multiple cycles. Each frame was acquired in 4 s intervals, and the video is played back at 6 fps. 
 
